RT Journal Article
T1 From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment.
A1 Vidal, Silvia
A1 Puig, Lluís
A1 Carrascosa-Carrillo, José-Manuel
A1 González-Cantero, Álvaro
A1 Ruiz-Carrascosa, José-Carlos
A1 Velasco-Pastor, Antonio-Manuel
K1 IL-17
K1 IL-17R
K1 Th17
K1 bimekizumab
K1 brodalumab
K1 ixekizumab
K1 monoclonal antibodies
K1 psoriasis
K1 secukinumab
AB The paradigm of psoriasis as a Th17-driven disease has evolved in the last years towards a much deeper knowledge of the complex pathways, mechanisms, cells, and messengers involved, highlighting the crucial role played by the IL-17 family of cytokines. All IL-17 isoforms signal through IL-17R. Five subunits of IL-17R have been described to date, which couple to form a homo- or hetero-receptor complex. Characteristically, IL-17RA is a common subunit in all hetero-receptors. IL-17RA has unique structural-containing a SEFIR/TILL domain-and functional-requiring ACT-1 for signaling-properties, enabling Th17 cells to act as a bridge between innate and adaptive immune cells. In psoriasis, IL-17RA plays a key role in pathogenesis based on: (a) IL-17A, IL-17F, and other IL-17 isoforms are involved in disease development; and (b) IL-17RA is essential for signaling of all IL-17 cytokines but IL-17D, whose receptor has not been identified to date. This article reviews current evidence on the biology and role of the IL-17 family of cytokines and receptors, with focus on IL-17RA, in psoriasis and some related comorbidities, and puts them in context with current and upcoming treatments.
YR 2021
FD 2021-06-23
LK http://hdl.handle.net/10668/18086
UL http://hdl.handle.net/10668/18086
LA en
DS RISalud
RD Apr 5, 2025